Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164


UC781 microbicide gel retains anti-HIV activity in cervicovaginal lavage fluids collected following twice-daily vaginal application.

Haaland RE, Evans-Strickfaden T, Holder A, Pau CP, McNicholl JM, Chaikummao S, Chonwattana W, Hart CE.

Antimicrob Agents Chemother. 2012 Jul;56(7):3592-6. doi: 10.1128/AAC.00452-12. Epub 2012 Apr 16.


The safety, persistence, and acceptability of an antiretroviral microbicide candidate UC781.

Bunge K, Macio I, Meyn L, Noguchi L, Parniak MA, Schwartz JL, Moncla B, Hillier S.

J Acquir Immune Defic Syndr. 2012 Aug 1;60(4):337-43. doi: 10.1097/QAI.0b013e3182575914.


Preclinical safety assessments of UC781 anti-human immunodeficiency virus topical microbicide formulations.

Patton DL, Sweeney YT, Balkus JE, Rohan LC, Moncla BJ, Parniak MA, Hillier SL.

Antimicrob Agents Chemother. 2007 May;51(5):1608-15. Epub 2007 Mar 12.


A randomized six-day safety study of an antiretroviral microbicide candidate UC781, a non-nucleoside reverse transcriptase inhibitor.

Schwartz JL, Kovalevsky G, Lai JJ, Ballagh SA, McCormick T, Douville K, Mauck CK, Callahan MM.

Sex Transm Dis. 2008 Apr;35(4):414-9. doi: 10.1097/OLQ.0b013e318162c4d8.


PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial.

Keller MJ, Zerhouni-Layachi B, Cheshenko N, John M, Hogarty K, Kasowitz A, Goldberg CL, Wallenstein S, Profy AT, Klotman ME, Herold BC.

J Infect Dis. 2006 Jan 1;193(1):27-35. Epub 2005 Nov 17.


Acceptability of UC781 gel as a rectal microbicide among HIV-uninfected women and men.

Ventuneac A, Carballo-Diéguez A, McGowan I, Dennis R, Adler A, Khanukhova E, Price C, Saunders T, Siboliban C, Anton P.

AIDS Behav. 2010 Jun;14(3):618-28. doi: 10.1007/s10461-009-9611-5. Epub 2009 Sep 11.


Assessment of cervicovaginal cytokine levels following exposure to microbicide Nisin gel in rabbits.

Aranha CC, Gupta SM, Reddy KV.

Cytokine. 2008 Jul;43(1):63-70. doi: 10.1016/j.cyto.2008.04.005. Epub 2008 May 29.


Design of tenofovir-UC781 combination microbicide vaginal gels.

Kiser PF, Mahalingam A, Fabian J, Smith E, Damian FR, Peters JJ, Katz DF, Elgendy H, Clark MR, Friend DR.

J Pharm Sci. 2012 May;101(5):1852-64. doi: 10.1002/jps.23089. Epub 2012 Feb 22.


Phase I randomized safety study of twice daily dosing of acidform vaginal gel: candidate antimicrobial contraceptive.

Keller MJ, Carpenter CA, Lo Y, Einstein MH, Liu C, Fredricks DN, Herold BC.

PLoS One. 2012;7(10):e46901. doi: 10.1371/journal.pone.0046901. Epub 2012 Oct 8.


Development and in vitro evaluation of a vaginal microbicide gel formulation for UAMC01398, a novel diaryltriazine NNRTI against HIV-1.

Grammen C, Ariën KK, Venkatraj M, Joossens J, Van der Veken P, Heeres J, Lewi PJ, Haenen S, Augustyns K, Vanham G, Augustijns P, Brouwers J.

Antiviral Res. 2014 Jan;101:113-21. doi: 10.1016/j.antiviral.2013.11.005. Epub 2013 Nov 20.


Vaginal gel formulation based on theaflavin derivatives as a microbicide to prevent HIV sexual transmission.

Yang J, Li L, Jin H, Tan S, Qiu J, Yang L, Ding Y, Jiang ZH, Jiang S, Liu S.

AIDS Res Hum Retroviruses. 2012 Nov;28(11):1498-508. doi: 10.1089/AID.2012.0084. Epub 2012 Sep 11.


First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy.

Anton PA, Saunders T, Elliott J, Khanukhova E, Dennis R, Adler A, Cortina G, Tanner K, Boscardin J, Cumberland WG, Zhou Y, Ventuneac A, Carballo-Diéguez A, Rabe L, McCormick T, Gabelnick H, Mauck C, McGowan I.

PLoS One. 2011;6(9):e23243. doi: 10.1371/journal.pone.0023243. Epub 2011 Sep 28.


Development and characterisation of a self-microemulsifying drug delivery systems (SMEDDSs) for the vaginal administration of the antiretroviral UC-781.

McConville C, Friend D.

Eur J Pharm Biopharm. 2013 Apr;83(3):322-9. doi: 10.1016/j.ejpb.2012.10.007. Epub 2012 Nov 16.


A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel.

Keller MJ, Madan RP, Torres NM, Fazzari MJ, Cho S, Kalyoussef S, Shust G, Mesquita PM, Louissaint N, Chen J, Cohen HW, Diament EC, Lee AC, Soto-Torres L, Hendrix CW, Herold BC.

PLoS One. 2011 Jan 25;6(1):e16475. doi: 10.1371/journal.pone.0016475.


Characterization of cyclodextrin inclusion complexes of the anti-HIV non-nucleoside reverse transcriptase inhibitor UC781.

Yang H, Parniak MA, Isaacs CE, Hillier SL, Rohan LC.

AAPS J. 2008 Dec;10(4):606-13. doi: 10.1208/s12248-008-9070-3. Epub 2008 Dec 17.


Lack of in vitro-in vivo correlation for a UC781-releasing vaginal ring in macaques.

McConville C, Smith JM, McCoy CF, Srinivasan P, Mitchell J, Holder A, Otten RA, Butera S, Doncel GF, Friend DR, Malcolm RK.

Drug Deliv Transl Res. 2015 Feb;5(1):27-37. doi: 10.1007/s13346-015-0216-4.


Distribution of a vaginal gel (Invisible Condom) before, during and after simulated sexual intercourse and its persistence when delivered by two different vaginal applicators: a magnetic resonance imaging study.

Omar RF, Trottier S, Brousseau G, Lamarre A, Alexandre Gagnon, Bergeron MG.

Contraception. 2008 Jun;77(6):447-55. doi: 10.1016/j.contraception.2008.01.015. Epub 2008 Apr 18.


A hot-melt extruded intravaginal ring for the sustained delivery of the antiretroviral microbicide UC781.

Clark MR, Johnson TJ, McCabe RT, Clark JT, Tuitupou A, Elgendy H, Friend DR, Kiser PF.

J Pharm Sci. 2012 Feb;101(2):576-87. doi: 10.1002/jps.22781. Epub 2011 Oct 4.


Dose-response relationship between tissue concentrations of UC781 and explant infectibility with HIV type 1 in the RMP-01 rectal safety study.

Richardson-Harman N, Mauck C, McGowan I, Anton P.

AIDS Res Hum Retroviruses. 2012 Nov;28(11):1422-33. doi: 10.1089/AID.2012.0073. Epub 2012 Sep 20.


Evaluation of immunologic markers in cervicovaginal fluid of HIV-infected and uninfected women: implications for the immunologic response to HIV in the female genital tract.

Sha BE, D'Amico RD, Landay AL, Spear GT, Massad LS, Rydman RJ, Warner NA, Padnick J, Ackatz L, Charles LA, Benson CA.

J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Nov 1;16(3):161-8.


Supplemental Content

Support Center